Search
Prasinezumab
go.drugbank.com/drugs/DB14788InvestigationalPrasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
AZD-8848
go.drugbank.com/drugs/DB14868InvestigationalAZD-8848 is under investigation in clinical trial NCT01818869 (To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects).
Etofamide
go.drugbank.com/drugs/DB13258ApprovedEtofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].
MOR-22
go.drugbank.com/drugs/DB17790ExperimentalMOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus warts in the oral cavity of HIV-positive patients.
Ecnoglutide
go.drugbank.com/drugs/DB19019InvestigationalEcnoglutide is under investigation in clinical trial NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity).
Nelonicline
go.drugbank.com/drugs/DB19040InvestigationalNelonicline is under investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia).
Eragidomide
go.drugbank.com/drugs/DB19242InvestigationalEragidomide is under investigation in clinical trial NCT04297124 (A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects).
TU-100
go.drugbank.com/drugs/DB12467InvestigationalTU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.
Pimodivir
go.drugbank.com/drugs/DB14974InvestigationalPimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).
Tomuzotuximab
go.drugbank.com/drugs/DB15178InvestigationalTomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).